Dyrskjøt Lars, Ostenfeld Marie S, Bramsen Jesper B, Silahtaroglu Asli N, Lamy Philippe, Ramanathan Ramshanker, Fristrup Niels, Jensen Jens L, Andersen Claus L, Zieger Karsten, Kauppinen Sakari, Ulhøi Benedicte P, Kjems Jørgen, Borre Michael, Orntoft Torben F
Molecular Diagnostic Laboratory, Department of Molecular Medicine, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark.
Cancer Res. 2009 Jun 1;69(11):4851-60. doi: 10.1158/0008-5472.CAN-08-4043.
microRNAs (miRNA) are involved in cancer development and progression, acting as tumor suppressors or oncogenes. Here, we profiled the expression of 290 unique human miRNAs in 11 normal and 106 bladder tumor samples using spotted locked nucleic acid-based oligonucleotide microarrays. We identified several differentially expressed miRNAs between normal urothelium and cancer and between the different disease stages. miR-145 was found to be the most down-regulated in cancer compared with normal, and miR-21 was the most up-regulated in cancer. Furthermore, we identified miRNAs that significantly correlated to the presence of concomitant carcinoma in situ. We identified several miRNAs with prognostic potential for predicting disease progression (e.g., miR-129, miR-133b, and miR-518c*). We localized the expression of miR-145, miR-21, and miR-129 to urothelium by in situ hybridization. We then focused on miR-129 that exerted significant growth inhibition and induced cell death upon transfection with a miR-129 precursor in bladder carcinoma cell lines T24 and SW780 cells. Microarray analysis of T24 cells after transfection showed significant miR-129 target down-regulation (P = 0.0002) and pathway analysis indicated that targets were involved in cell death processes. By analyzing gene expression data from clinical tumor samples, we identified significant expression changes of target mRNA molecules related to the miRNA expression. Using luciferase assays, we documented a direct link between miR-129 and the two putative targets GALNT1 and SOX4. The findings reported here indicate that several miRNAs are differentially regulated in bladder cancer and may form a basis for clinical development of new biomarkers for bladder cancer.
微小RNA(miRNA)参与癌症的发生和发展,可作为肿瘤抑制因子或癌基因发挥作用。在此,我们使用基于锁核酸的点阵寡核苷酸微阵列分析了11例正常膀胱组织样本和106例膀胱肿瘤样本中290种独特人类miRNA的表达情况。我们鉴定出了正常尿路上皮与癌症之间以及不同疾病阶段之间几种差异表达的miRNA。与正常组织相比,miR-145在癌症中表达下调最为明显,而miR-21在癌症中表达上调最为显著。此外,我们还鉴定出了与原位癌存在显著相关的miRNA。我们发现了几种具有预测疾病进展预后潜力的miRNA(如miR-129、miR-133b和miR-518c*)。我们通过原位杂交将miR-145、miR-21和miR-129的表达定位到尿路上皮。随后,我们聚焦于miR-129,在膀胱癌细胞系T24和SW780细胞中转染miR-129前体后,其发挥了显著的生长抑制作用并诱导细胞死亡。对转染后的T24细胞进行微阵列分析显示,miR-129靶标显著下调(P = 0.0002),通路分析表明这些靶标参与细胞死亡过程。通过分析临床肿瘤样本的基因表达数据,我们确定了与miRNA表达相关的靶标mRNA分子的显著表达变化。利用荧光素酶检测,我们证实了miR-129与两个假定靶标GALNT1和SOX4之间存在直接联系。本文报道的研究结果表明,几种miRNA在膀胱癌中存在差异调节,可能为膀胱癌新生物标志物的临床开发奠定基础。